Summary.-The results of intravenous chemotherapy for advanced squamous cell carcinoma of the head and neck in 50 patients are presented. Forty patients were treated with methotrexate alone-3 patients showed partial regression of disease and a further 7 were controlled for periods of up to 4 months. Of those patients who failed to respond, or who relapsed on methotrexate, 16 were treated with combination chemotherapy. One patient showed complete regression of disease, 2 partial regression and in 2 others control was achieved for up to 4 months. A further 10 patients were treated with combination chemotherapy only, with no previous methotrexate. In this group no objective regressions were noted and only one patient was controlled for a period of 14 months. It is suggested that intravenous chemotherapy in advanced squamous cell carcinoma of the head and neck is of doubtful value. PATIENTS In all patients the blood urea concentration was measured before starting treatment and a full blood count was performed before each injection. They were examined regularly for oral ulceration and questioned as to whether nausea or diarrhoea had been experienced.
Forty patients were treated on this regimen. All had received irradiation previously and 18 had undergone some form of major surgery for recurrent disease. There is close co-operation at this hospital between radiotherapists, general surgeons and plastic surgeons and many of these patients had been subjected to major excision and reconstruction procedures in an attempt to eradicate disease. Chemotherapy was started only when radiotherapy and surgery had failed to control the condition.
In 1970 a modification of the Costanzi and Coltman (1969) regimen of combination chemotherapy was employed for solid tumours (Hanham, Newton and Westbury, 1971) . Those patients with squamous cell carcinoma of the head and neck who had failed to respond to intravenous methotrexate were transferred to this regimen. Sixteen patients were treated in this way and limited early success with combination chemotherapy led to its use as the initial chemotherapeutic regimen in a further 10 patients.
All patients were given combination chemotherapy as a 5-day course with 3 weeks' lapse between courses. The drugs and their dosages are given in Table I . . Major surgery in addition to radiotherapy does not appear to prejudice the chances of success with chemotherapy. All the patients showing actual regression of disease had been subjected to some form of surgery in addition to radiotherapy.
No particular primary site appears more, or less, sensitive than any other to chemotherapy.
Of the 50 patients in this series, 6 (12-0%) had chest x-rays demonstrating pulmonary metastases.
DISCUSSION
In the early 1960s the chemotherapeutic treatment of choice for advanced squamous cell carcinoma of the head and neck at this hospital was intraarterial perfusion with methotrexate (Westbury et al., 1962; Westbury, 1963 The question of optimum dosage can again be raised but toxic effects were noted in 11 patients and doubtless higher doses would have increased both the number and severity of such effects.
It can be argued that such symptoms as oral ulceration, nausea, alopecia, neuropathy and the risk of infection and haemorrhage can all be justified to obtain regression of otherwise incurable disease. Even in the best series, however, such regressions are usually brief and it is considered of doubtful benefit to give someone with incurable, often disfiguring, disease a few more months of life merely to suffer the side-effects of intensive chemotherapy.
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